Back to Pipeline

Retifanlimab (PD-1)


Retifanlimab (INCMGA0012) is an investigational monoclonal antibody that inhibits PD-1. Retifanlimab is currently being evaluated as monotherapy in registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer. In 2017, Incyte entered into an exclusive global collaboration and license agreement with MacroGenics, Inc. for global rights to INCMGA0012. In July 2019, we obtained the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong (China), Macau (China) and Taiwan region.